Galapagos CEO Upbeat Despite Filgotinib Upset In US
Focus Now On Jyseleca Launches In Europe
Executive Summary
Onno van de Stolpe has told Scrip it will take time to win investor confidence back after more disappointing news about the JAK inhibitor but Galapagos has "the pipeline and the cash in the organization to do so."
You may also be interested in...
Galapagos Defends High-Risk High-Reward R&D Strategy
Following a trio of high-profile setbacks, the Belgian biotech is looking to fill the gap between the European launches of its rheumatoid arthritis drug Jyseleca and its programs back in Phase II via in-licensing and M&A.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.
Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020
Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.